Literature DB >> 33091120

Young children with medulloblastoma: important open questions and the high-risk dilemma.

Martin Mynarek1,2, Stefan Rutkowski1.   

Abstract

Entities:  

Year:  2020        PMID： 33091120      PMCID： PMC7746935          DOI： 10.1093/neuonc/noaa241

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.

Authors:  Léa Guerrini-Rousseau; Christelle Dufour; Pascale Varlet; Julien Masliah-Planchon; Franck Bourdeaut; Marine Guillaud-Bataille; Rachid Abbas; Anne-Isabelle Bertozzi; Fanny Fouyssac; Sophie Huybrechts; Stéphanie Puget; Brigitte Bressac-De Paillerets; Olivier Caron; Nicolas Sevenet; Marina Dimaria; Sophie Villebasse; Olivier Delattre; Dominique Valteau-Couanet; Jacques Grill; Laurence Brugières
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

2.  Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221).

Authors:  Lucie Lafay-Cousin; Eric Bouffet; Douglas Strother; Vasilisa Rudneva; Cynthia Hawkins; Charles Eberhart; Craig Horbinski; Linda Heier; Mark Souweidane; Chris Williams-Hughes; Arzu Onar-Thomas; Catherine A Billups; Maryam Fouladi; Paul Northcott; Giles Robinson; Amar Gajjar
Journal:  J Clin Oncol       Date:  2019-11-27       Impact factor: 44.544

3.  Genomics Paves the Way for Better Infant Medulloblastoma Therapy.

Authors:  Giles W Robinson; Amar Gajjar
Journal:  J Clin Oncol       Date:  2020-04-30       Impact factor: 44.544

4.  Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial.

Authors:  Girish Dhall; Sharon H O'Neil; Lingyun Ji; Kelley Haley; Ashley M Whitaker; Marvin D Nelson; Floyd Gilles; Sharon L Gardner; Jeffrey C Allen; Albert S Cornelius; Kamnesh Pradhan; James H Garvin; Randal S Olshefski; Juliette Hukin; Melanie Comito; Stewart Goldman; Mark P Atlas; Andrew W Walter; Stephen Sands; Richard Sposto; Jonathan L Finlay
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

5.  Neuropsychological functioning of children treated with intensive chemotherapy followed by myeloablative consolidation chemotherapy and autologous hematopoietic cell rescue for newly diagnosed CNS tumors: an analysis of the Head Start II survivors.

Authors:  Stephen A Sands; Jennifer A Oberg; Sharon L Gardner; Jennifer A Whiteley; Julia L Glade-Bender; Jonathan L Finlay
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

6.  Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.

Authors:  Giles W Robinson; Vasilisa A Rudneva; Ivo Buchhalter; Catherine A Billups; Sebastian M Waszak; Kyle S Smith; Daniel C Bowers; Anne Bendel; Paul G Fisher; Sonia Partap; John R Crawford; Tim Hassall; Daniel J Indelicato; Frederick Boop; Paul Klimo; Noah D Sabin; Zoltan Patay; Thomas E Merchant; Clinton F Stewart; Brent A Orr; Jan O Korbel; David T W Jones; Tanvi Sharma; Peter Lichter; Marcel Kool; Andrey Korshunov; Stefan M Pfister; Richard J Gilbertson; Robert P Sanders; Arzu Onar-Thomas; David W Ellison; Amar Gajjar; Paul A Northcott
Journal:  Lancet Oncol       Date:  2018-05-16       Impact factor: 41.316

7.  Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.

Authors:  Martin Mynarek; Katja von Hoff; Torsten Pietsch; Holger Ottensmeier; Monika Warmuth-Metz; Brigitte Bison; Stefan Pfister; Andrey Korshunov; Tanvi Sharma; Natalie Jaeger; Marina Ryzhova; Olga Zheludkova; Andrey Golanov; Elisabeth Jane Rushing; Martin Hasselblatt; Arend Koch; Ulrich Schüller; Andreas von Deimling; Felix Sahm; Martin Sill; Markus J Riemenschneider; Hildegard Dohmen; Camelia Maria Monoranu; Clemens Sommer; Ori Staszewski; Christian Mawrin; Jens Schittenhelm; Wolfgang Brück; Katharina Filipski; Christian Hartmann; Matthias Meinhardt; Klaus Pietschmann; Christine Haberler; Irene Slavc; Nicolas U Gerber; Michael Grotzer; Martin Benesch; Paul Gerhardt Schlegel; Frank Deinlein; André O von Bueren; Carsten Friedrich; Björn-Ole Juhnke; Denise Obrecht; Gudrun Fleischhack; Robert Kwiecien; Andreas Faldum; Rolf Dieter Kortmann; Marcel Kool; Stefan Rutkowski
Journal:  J Clin Oncol       Date:  2020-04-24       Impact factor: 44.544

8.  The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes.

Authors:  D Hicks; G Rafiee; E C Schwalbe; C I Howell; J C Lindsey; R M Hill; A J Smith; P Adidharma; C Steel; S Richardson; L Pease; M Danilenko; S Crosier; A Joshi; S B Wharton; T S Jacques; B Pizer; A Michalski; D Williamson; S Bailey; S C Clifford
Journal:  Neuropathol Appl Neurobiol       Date:  2020-09-01       Impact factor: 8.090

9.  Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment.

Authors:  Holger Ottensmeier; Paul G Schlegel; Matthias Eyrich; Johannes E Wolff; Björn-Ole Juhnke; Katja von Hoff; Stefanie Frahsek; Rene Schmidt; Andreas Faldum; Gudrun Fleischhack; Andre von Bueren; Carsten Friedrich; Anika Resch; Monika Warmuth-Metz; Jürgen Krauss; Rolf D Kortmann; Udo Bode; Joachim Kühl; Stefan Rutkowski
Journal:  PLoS One       Date:  2020-01-23       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.